Skip to main content

      Unlocking value in an era of widespread tech adoption

      Life Sciences technology leaders largely see themselves as innovators or fast followers, adopting new tools once proven or leading selectively where the business case is clear. Companies in the sector have moved beyond experimentation and into broad adoption of core technologies such as AI, data analytics and cybersecurity. However, while digital investment is widespread, value realisation remains constrained.

      Key findings from our research



      are achieving significant value realisation on their technology investments


      report digital initiatives generate less than 1% of annual revenue — highlighting a scale/value capture gap



      KPMG Global tech report 2026: Life Sciences

      A snapshot on technology adoption, investment, and value realisation


      The era of isolated digital experiments must come to an end. To bridge the disparity between ambition and achievement, life sciences leaders should enforce a strict scaling mandate: no new AI pilot should move forward without a validated path to production and a ringfenced budget for the complex work of enterprise integration.

      Irene Chu

      Partner
      Head of New Economy, Head of Life Sciences, ESG Reporting Lead
      Hong Kong SAR

      KPMG China


      Disciplined governance has served the sector well for stability, but it has also created a maturity plateau. Moving from 'managed' to 'optimised' requires a fundamental shift toward a product operating model, where core technology platforms are continuously refined by dedicated teams rather than treated as static project deliverables.

      Stanley Sum

      Partner
      Head of Technology Consulting
      Greater Bay Area

      KPMG China

      Why download the report?

      By downloading Global tech report 2026: Life Sciences, you will:

      • Learn where Life Sciences companies are really winning with technology — and where they aren’t
      • Explore the value capture gap and practical guidance on how to close it
      • Gain executive-ready insights that help to support sharper decision-making on where to invest, scale or stop

      About the research

      The insights in this report were derived from the KPMG Global Tech Report 2026, a survey of 2,500 technology leaders from 24 countries across eight industries, Life Sciences included. Survey respondents represented organisations with annual operating budgets or revenues above US$100 million and included a diverse group of technology leaders, such as chief data or digital officers, CIOs, CTOs, CISOs, chief AI officers and others.

      The Life Sciences insights are based on the views of 124 Life Sciences technology function leaders.

      Our insights

      Explore how organisations navigate today’s emerging tech — and prepare for what’s next

      Life sciences organisations have embedded AI deeply into their operations — from R&D and clinical trials to supply chains and commercial functions.

      Exploring CEO views on economic growth, technology investments, workforce and ESG

      Contact us

      Irene Chu
      Irene Chu

      Partner, Head of New Economy, Head of Life Sciences, ESG Reporting Lead

      Hong Kong SAR

      KPMG China

      Stanley Sum
      Stanley Sum

      Partner, Head of Technology Consulting

      Greater Bay Area

      KPMG China


      Submit RFP

      Find out how KPMG's expertise can help you and your company.